<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965220</url>
  </required_header>
  <id_info>
    <org_study_id>HLX208-MEK-001</org_study_id>
    <nct_id>NCT04965220</nct_id>
  </id_info>
  <brief_title>HLX208 (BRAF V600E Inhibitor) in Combination With Trimetinib in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HLX208 (BRAF V600E Inhibitor) in Combination With Trimetinib in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and initial&#xD;
      efficacy of HLX208 (BRAF V600E inhibitor) in combination with trimetinib in patients with&#xD;
      advanced solid tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>from first dose to the end of Cycle 1 (each cycle is 21 days)</time_frame>
    <description>maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RP2D</measure>
    <time_frame>from first dose to the end of Cycle 1 (each cycle is 21 days)</time_frame>
    <description>Recommended dose for phase II clinical trials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of HLX208</measure>
    <time_frame>from first dose to the beginning of Cycle 4 (each cycle is 21 days)</time_frame>
    <description>pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>from first dose to the last patient was followed up for 6 month</time_frame>
    <description>The number of patients with CR or PR divided by the total number of treated patients whose disease was measurable at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)of HLX208</measure>
    <time_frame>from first dose to the beginning of Cycle 4 (each cycle is 21 days)</time_frame>
    <description>pharmacokinetics</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>ATC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary brain tumor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRC(KRAS mutant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>other solid tumor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX 208</intervention_name>
    <description>take orally</description>
    <arm_group_label>ATC</arm_group_label>
    <arm_group_label>CRC(KRAS mutant)</arm_group_label>
    <arm_group_label>Primary brain tumor</arm_group_label>
    <arm_group_label>other solid tumor</arm_group_label>
    <other_name>trametinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18Y≤Age≤75Y&#xD;
&#xD;
          -  Good Organ Function&#xD;
&#xD;
          -  Expected survival time ≥ 3 months&#xD;
&#xD;
          -  Metastatic/recurrent advanced BRAF+ solid tumors that have been diagnosed&#xD;
             histologically and have failed standard treatment&#xD;
&#xD;
          -  Previous failure to standard treatment, intolerance to standard treatment, absence of&#xD;
             standard treatment, or insuitability for standard treatment at this stage.&#xD;
&#xD;
          -  ECOG score 0-1;&#xD;
&#xD;
          -  Expected survival time of more than 3 months;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with BRAF inhibitors or MEK inhibitors&#xD;
&#xD;
          -  Symptomatic brain or meningeal metastases (unless the patient has been on &gt; treatment&#xD;
             for 6 months, has no evidence of progress on imaging within 4 weeks prior to initial&#xD;
             administration, and tumor-related clinical symptoms are stable).&#xD;
&#xD;
          -  Current or former patients with interstitial lung disease;&#xD;
&#xD;
          -  Active clinical severe infection;&#xD;
&#xD;
          -  A history of other malignancies within two years, except for cured carcinoma in situ&#xD;
             of the cervix or basal cell carcinoma of the skin.&#xD;
&#xD;
          -  Other anti-tumor treatments, such as chemotherapy, targeted therapy, or radiation&#xD;
             therapy (except palliative radiation therapy), may be given during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhang Li, leading PI</last_name>
    <phone>13902282893</phone>
    <email>zhangli@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guo ye, PI</last_name>
    <email>pattrickguo@gmail.com</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

